lavendamycin
Description
Lavendamycin is a natural product antibiotic produced by Streptomyces lavendulae. It exhibits potent antitumor activity, particularly against leukemia cells, and has been studied for its potential as a chemotherapeutic agent. Its mechanism of action involves DNA intercalation, inhibiting DNA replication and transcription. Lavendamycin is a complex molecule with a unique structure containing a quinoline ring system and a cyclopropyl group. Its synthesis has been a challenging undertaking due to the presence of multiple chiral centers. Several research groups have investigated its synthesis, with various strategies employed to achieve its preparation. However, its clinical application has been limited by its toxicity and the development of resistance. Ongoing research focuses on understanding its mechanism of action and developing analogs with improved therapeutic profiles.'
lavendamycin: from Streptomyces lavendulae; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 100585 |
MeSH ID | M0106488 |
Synonyms (14)
Synonym |
---|
nsc322370 |
nsc-322370 |
81645-09-2 |
lavendamycin |
1-(7-amino-5,8-dioxoquinolin-2-yl)-4-methyl-9h-pyrido[3,4-b]indole-3-carboxylic acid |
nsc 322370 |
unii-xl8988yp79 |
xl8988yp79 , |
9h-pyrido(3,4-b)indole-3-carboxylic acid, 1-(7-amino-5,8-dihydro-5,8-dioxo-2-quinolinyl)-4-methyl- |
1-(7-amino-5,8-dihydro-5,8-dioxo-2-quinolinyl)-4-methyl-9h-pyrido(3,4-b)indole-3-carboxylic acid |
Q1808882 |
1-(7-amino-5,8-dioxo-5,8-dihydroquinolin-2-yl)-4-methyl-9h-pyrido[3,4-b]indole-3-carboxylic acid |
DTXSID401002112 |
AKOS040747018 |
Research Excerpts
Overview
Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities.
Excerpt | Reference | Relevance |
---|---|---|
"Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities. " | ( Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin. Abraham, RT; Behforouz, M; Cai, W; Fang, Y; Linardic, CM; Richardson, DA, 2003) | 1.98 |
Toxicity
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (18.75) | 18.7374 |
1990's | 2 (12.50) | 18.2507 |
2000's | 8 (50.00) | 29.6817 |
2010's | 3 (18.75) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.64) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |